Capecitabine-associated hand–foot–skin reaction is an independent clinical predictor of improved survival in patients with colorectal cancer
Open Access
- 2 October 2012
- journal article
- research article
- Published by Springer Science and Business Media LLC in British Journal of Cancer
- Vol. 107 (10), 1678-1683
- https://doi.org/10.1038/bjc.2012.434
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Correlation of capecitabine-induced skin toxicity with treatment efficacy in patients with metastatic colorectal cancer: results from the German AIO KRK-0104 trialBritish Journal of Cancer, 2011
- XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated resultsBritish Journal of Cancer, 2011
- Cetuximab Plus Capecitabine and Irinotecan Compared With Cetuximab Plus Capecitabine and Oxaliplatin As First-Line Treatment for Patients With Metastatic Colorectal Cancer: AIO KRK-0104—A Randomized Trial of the German AIO CRC Study GroupJournal of Clinical Oncology, 2011
- Placebo-Controlled Trial to Determine the Effectiveness of a Urea/Lactic Acid–Based Topical Keratolytic Agent for Prevention of Capecitabine-Induced Hand-Foot Syndrome: North Central Cancer Treatment Group Study N05C5Journal of Clinical Oncology, 2010
- Study of Low-Dose Capecitabine Monotherapy for Metastatic Breast CancerChemotherapy, 2010
- Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority studyAnnals of Oncology, 2008
- Randomized Phase III Study of Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid Plus Oxaliplatin As First-Line Therapy for Metastatic Colorectal CancerJournal of Clinical Oncology, 2008
- Management of hand-foot syndrome induced by capecitabineJournal of Oncology Pharmacy Practice, 2006
- Capecitabine as Adjuvant Treatment for Stage III Colon CancerThe New England Journal of Medicine, 2005
- Thymidine phosphorylase (platelet-derived endothelial-cell growth factor) in cancer biology and treatmentThe Lancet Oncology, 2005